Rituximab vs. Tocilizimab for Scleroderma: Which is Better? Dr. Janet Pope discusses abstract OP0295 presented at Eular 2024 in Vienna, Austria. https://t.co/70YF2wxwj5 https://t.co/8BHCafFs3u

Has JAK POT Hit the Spot About Infection Risk? Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria. https://t.co/vN2VZYGqbE https://t.co/MQ3QCJU4SW

DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria. https://t.co/gKJRygBeq0 https://t.co/2NTNYJLPNZ

Damage in Childhood Lupus Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise. https://t.co/wCygK0LGvd https://t.co/tm8LTI28mh

RA: update for women of child bearing potential (and men!) Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients. https://t.co/RrkR2V3CI3 https://t.co/CRXUKxUqF2

Difficult-to-treat Rheumatoid Arthritis: Validation of the EULAR Definition Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria. https://t.co/oc3Aj60KsM https://t.co/40FMjbKEHF

EULAR 2024 Daily Recap: Days 1 & 2 Dr. Jack Cush moderates EULAR 2024 RECAP for days 1 & 2 with Drs. Mrinalini Day and Yuz Yusof in Vienna, Austria. https://t.co/gRMVUXhTxw https://t.co/YV8vjVUCJn

Rituximab to Treat Systemic Features of Sjogren's Dr. Yuz Yusof discusses abstract OP0076 presented at Eular 2024 in Vienna, Austria. https://t.co/9oJNz12cCI https://t.co/bZxpbf3PT9

Update on Sjogren's disease trials With better endpoint and patient selection strategy over the last 4 years, many new therapies have met their endpoints/shown promising signal in the Phase 2 RCTs in Sjogren's disease. https://t.co/qMxEX73BsM https://t.co/CQWaAIO4IK

New Treatments for Systemic Sclerosis aHSCT for SSc has been proven the most effective treatment strategy with regard to overall and event free survival in selected patients.2 But a key limitation is its toxicity, and new treatment options are needed. https://t.co/xUI0plrk42 https://t.co/DqGUhU6D1Z

Camels and psoriatic arthritis - a new treatment link https://t.co/0SQt3UPmKu https://t.co/zvwH9iYtxX

EULAR 2024 – Day 4 Report The final day of EULAR 2024 was rich in posters, Late-breaking oral presentations and EULAR updates and recommendations. Below is a synopsis of the half-day's action. https://t.co/1lQcu1beOm https://t.co/QHMcFzaG48